Hospital
Central Washington Health Services Association
Central Washington Health Services Association was paid $63.42M by Medicaid between Jan 2018 and Dec 2024, across 578 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 26% of everything it billed.
33Billing provider infoCENTRAL WASHINGTON HEALTH SERVICES ASSOCIATION
WENATCHEE, WA 98801
WENATCHEE, WA 98801
33aNPI1306883228assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$63.42M
24GClaims2,026,234
24DCodes billed578
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#9 of 49
Median peer was paid$20.06M
This provider vs. median3.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JONES, ANDREW controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 171,760 | $4.99M | |
| 2019 | 257,638 | $7.46M | |
| 2020 | 242,173 | $6.94M | |
| 2021 | 295,245 | $8.03M | |
| 2022 | 297,921 | $9.01M | |
| 2023 | 375,768 | $12.48M | |
| 2024incomplete | 385,729 | $14.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 26% | 193,055 | 155,578 | $16.59M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.7% | 49,433 | 45,320 | $6.12M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.2% | 17,440 | 14,065 | $5.17M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.5% | 48,249 | 42,671 | $4.14M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 7,190 | 6,943 | $1.40M |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 1.9% | 1,356 | 1,260 | $1.20M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 12,705 | 9,912 | $1.13M |
| 96415 | 1.7% | 4,589 | 3,405 | $1.06M | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.7% | 5,179 | 3,217 | $1.05M |
| J9271 | Injection, pembrolizumab, 1 mg | 1.5% | 275 | 215 | $976K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 5,564 | 5,258 | $819K |
| 59025 | Fetal non-stress test | 1.2% | 4,677 | 2,856 | $751K |
566 more codes
| C9257 | Injection, bevacizumab, 0.25 mg | 1.1% | 3,432 | $729K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.1% | 340 | $715K |
| 96367 | 1.1% | 10,256 | $701K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 5,341 | $700K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.1% | 2,783 | $696K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 3,076 | $672K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 1,681 | $613K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,509 | $601K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 941 | $531K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 4,270 | $528K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 11,781 | $507K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,930 | $474K |
| J9312 | Injection, rituximab, 10 mg | <1% | 336 | $469K |
| 64615 | <1% | 2,042 | $449K | |
| 29581 | <1% | 3,509 | $398K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,134 | $384K |
| J9310 | Injection, rituximab, 100 mg | <1% | 280 | $373K |
| 80053 | Comprehensive metabolic panel | <1% | 73,639 | $356K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 756 | $339K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,217 | $339K |
| G0378 | Hospital observation service, per hour | <1% | 7,758 | $311K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,248 | $303K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,763 | $293K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 6,201 | $281K |
| 76830 | Ultrasound, transvaginal | <1% | 2,894 | $253K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 669 | $247K |
| 44970 | <1% | 79 | $240K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 17,604 | $238K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 3,582 | $231K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,518 | $208K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,212 | $188K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,882 | $182K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 28,585 | $176K |
| 97597 | <1% | 2,847 | $172K | |
| 12001 | <1% | 752 | $155K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 607 | $154K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 17,609 | $153K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 118 | $149K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,241 | $144K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 446 | $144K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 445 | $140K |
| 93971 | <1% | 1,715 | $139K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,565 | $139K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 88,608 | $138K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 10,390 | $133K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 21,947 | $128K |
| 88142 | <1% | 9,283 | $127K | |
| 99285 | Emergency room visit (most serious) | <1% | 1,085 | $123K |
| 58300 | <1% | 975 | $122K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 25,297 | $117K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 74 | $111K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 80 | $111K |
| 80050 | General health panel | <1% | 15,190 | $108K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 29,076 | $100K |
| 76770 | <1% | 918 | $99K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 19,175 | $98K |
| 93976 | <1% | 1,914 | $98K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,114 | $96K |
| 52356 | <1% | 36 | $95K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 6,460 | $95K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,840 | $94K |
| 97162 | <1% | 2,178 | $92K | |
| 82728 | <1% | 14,943 | $90K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,127 | $89K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,890 | $89K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 286 | $88K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 7,173 | $88K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 27,724 | $88K |
| 87507 | <1% | 805 | $87K | |
| 70496 | <1% | 456 | $87K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,260 | $86K |
| 95886 | <1% | 900 | $85K | |
| 86780 | <1% | 9,505 | $85K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 172 | $83K |
| 80061 | Lipid panel | <1% | 21,455 | $81K |
| 92551 | <1% | 2,799 | $78K | |
| 76801 | <1% | 1,596 | $71K | |
| 93017 | <1% | 919 | $70K | |
| 90715 | <1% | 3,881 | $70K | |
| 64405 | <1% | 211 | $69K | |
| 52000 | <1% | 112 | $68K | |
| 20610 | <1% | 610 | $68K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 130 | $62K |
| 47562 | <1% | 25 | $62K | |
| 87653 | <1% | 4,288 | $60K | |
| 11102 | <1% | 313 | $59K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,401 | $59K |
| 82607 | <1% | 9,052 | $55K | |
| 92526 | <1% | 1,079 | $54K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,518 | $54K |
| 97161 | <1% | 1,155 | $53K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,671 | $53K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 24,415 | $52K |
| 96523 | <1% | 1,457 | $52K | |
| 84484 | <1% | 10,204 | $51K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 80,587 | $49K |
| 84439 | <1% | 7,745 | $49K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 2,977 | $49K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,843 | $47K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 697 | $47K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 685 | $47K |
| 87081 | <1% | 7,918 | $46K | |
| 94060 | <1% | 1,621 | $45K | |
| 87077 | <1% | 13,936 | $45K | |
| 86140 | <1% | 18,172 | $40K | |
| 0002A | <1% | 1,275 | $39K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,622 | $39K |
| 90686 | <1% | 4,246 | $38K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,023 | $37K |
| 0001A | <1% | 1,554 | $37K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,234 | $36K |
| 83540 | <1% | 11,288 | $35K | |
| 82570 | <1% | 11,152 | $35K | |
| 17110 | <1% | 302 | $33K | |
| 86900 | <1% | 8,547 | $33K | |
| J3490 | Unclassified drugs | <1% | 23,237 | $33K |
| 87040 | <1% | 4,074 | $32K | |
| 83605 | <1% | 6,071 | $32K | |
| 12011 | <1% | 152 | $32K | |
| 11104 | <1% | 131 | $32K | |
| 83970 | <1% | 2,190 | $32K | |
| 70498 | <1% | 496 | $30K | |
| 80074 | <1% | 4,087 | $30K | |
| 92550 | <1% | 698 | $29K | |
| G0008 | Administration of influenza virus vaccine | <1% | 5,278 | $29K |
| 95117 | <1% | 1,414 | $29K | |
| 86706 | <1% | 6,417 | $29K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,287 | $28K |
| 83880 | <1% | 3,846 | $28K | |
| 86703 | <1% | 6,790 | $28K | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 566 | $27K |
| 86850 | <1% | 8,414 | $27K | |
| 36591 | <1% | 4,873 | $27K | |
| 76937 | <1% | 843 | $26K | |
| 87070 | <1% | 5,989 | $25K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 261 | $24K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,440 | $24K |
| 83001 | <1% | 1,882 | $23K | |
| 84481 | <1% | 4,083 | $22K | |
| 94726 | <1% | 1,575 | $22K | |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 20 | $22K |
| 84146 | <1% | 1,914 | $22K | |
| 94729 | <1% | 2,037 | $22K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 2,992 | $21K |
| 31575 | <1% | 294 | $21K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 146 | $21K |
| 80047 | <1% | 9,864 | $21K | |
| 84702 | <1% | 3,990 | $20K | |
| 12002 | <1% | 126 | $20K | |
| 88307 | <1% | 778 | $20K | |
| 95115 | <1% | 923 | $20K | |
| 80076 | <1% | 8,605 | $20K | |
| 85379 | <1% | 3,940 | $20K | |
| 64483 | <1% | 43 | $19K | |
| 88342 | <1% | 2,118 | $19K | |
| 10060 | <1% | 105 | $19K | |
| 92587 | <1% | 451 | $19K | |
| 84153 | <1% | 3,409 | $18K | |
| 85652 | <1% | 14,317 | $18K | |
| 49083 | <1% | 49 | $18K | |
| 82784 | <1% | 2,996 | $18K | |
| 85027 | <1% | 10,659 | $17K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 533 | $17K |
| 86480 | <1% | 936 | $17K | |
| 58301 | <1% | 149 | $17K | |
| C1776 | Joint device (implantable) | <1% | 68 | $16K |
| 69210 | <1% | 259 | $16K | |
| 87340 | <1% | 7,316 | $16K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 61 | $16K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 286 | $16K |
| 87210 | <1% | 5,039 | $16K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 12 | $16K |
| 83013 | <1% | 552 | $16K | |
| 86901 | <1% | 8,547 | $16K | |
| 71271 | <1% | 218 | $16K | |
| 86803 | <1% | 4,930 | $15K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 265 | $15K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 512 | $15K |
| 72100 | <1% | 2,274 | $15K | |
| 93296 | <1% | 1,790 | $15K | |
| 31231 | <1% | 195 | $14K | |
| 82247 | <1% | 1,869 | $14K | |
| 83735 | <1% | 10,863 | $14K | |
| 82043 | <1% | 9,455 | $14K | |
| 17000 | <1% | 297 | $14K | |
| 70486 | <1% | 295 | $14K | |
| 81001 | <1% | 19,369 | $14K | |
| 83690 | <1% | 17,998 | $14K | |
| 74018 | <1% | 2,031 | $14K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,302 | $14K |
| 73630 | <1% | 1,612 | $13K | |
| 92083 | <1% | 821 | $13K | |
| 92557 | <1% | 724 | $13K | |
| 96376 | <1% | 6,248 | $13K | |
| 73564 | <1% | 1,849 | $13K | |
| 82533 | <1% | 985 | $13K | |
| 93226 | <1% | 369 | $13K | |
| 57454 | <1% | 40 | $13K | |
| 86762 | <1% | 4,908 | $12K | |
| 95885 | <1% | 129 | $12K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 258 | $12K |
| 92579 | <1% | 279 | $12K | |
| 92567 | <1% | 1,012 | $11K | |
| 85610 | <1% | 10,082 | $11K | |
| 73610 | <1% | 2,033 | $11K | |
| 70491 | <1% | 52 | $11K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 795 | $11K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 188 | $11K |
| 87428 | <1% | 3,786 | $11K | |
| 93970 | <1% | 111 | $11K | |
| 94010 | <1% | 445 | $11K | |
| 84403 | <1% | 1,186 | $11K | |
| 88304 | <1% | 1,794 | $10K | |
| 71250 | <1% | 228 | $10K | |
| 84466 | <1% | 2,405 | $10K | |
| 73110 | <1% | 1,359 | $10K | |
| 74420 | <1% | 72 | $10K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 530 | $10K |
| 82746 | <1% | 2,700 | $10K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 489 | $9K |
| 86003 | <1% | 977 | $9K | |
| 29075 | <1% | 59 | $9K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 27 | $9K |
| 87147 | <1% | 3,471 | $9K | |
| 76536 | <1% | 98 | $9K | |
| 81025 | <1% | 15,090 | $9K | |
| 87186 | <1% | 5,825 | $9K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 33 | $9K |
| 85007 | <1% | 3,892 | $9K | |
| 11981 | <1% | 13 | $8K | |
| 82248 | <1% | 2,240 | $8K | |
| 73130 | <1% | 1,329 | $8K | |
| 83002 | <1% | 996 | $8K | |
| 95816 | <1% | 53 | $8K | |
| 92235 | <1% | 90 | $8K | |
| 73030 | <1% | 1,333 | $8K | |
| 72131 | <1% | 181 | $8K | |
| 85018 | <1% | 3,525 | $8K | |
| 92504 | <1% | 101 | $8K | |
| 83655 | <1% | 636 | $7K | |
| 87563 | <1% | 989 | $7K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $7K |
| 82670 | <1% | 707 | $7K | |
| 85014 | <1% | 2,238 | $7K | |
| 72040 | <1% | 1,588 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 963 | $6K |
| 92025 | <1% | 79 | $6K | |
| 97167 | <1% | 130 | $6K | |
| 73502 | <1% | 632 | $6K | |
| 88341 | <1% | 853 | $6K | |
| 97129 | <1% | 29 | $6K | |
| 92610 | <1% | 145 | $6K | |
| 17311 | <1% | 32 | $6K | |
| 73140 | <1% | 655 | $6K | |
| 99152 | <1% | 2,894 | $6K | |
| 86431 | <1% | 2,125 | $6K | |
| 87045 | <1% | 1,032 | $5K | |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | <1% | 25 | $5K |
| 86038 | <1% | 992 | $5K | |
| 74174 | <1% | 15 | $5K | |
| 87338 | <1% | 791 | $5K | |
| 11900 | <1% | 39 | $5K | |
| 92552 | <1% | 232 | $5K | |
| 82075 | <1% | 1,433 | $5K | |
| 84145 | <1% | 885 | $5K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 80 | $5K |
| 72110 | <1% | 296 | $4K | |
| 95910 | <1% | 93 | $4K | |
| 43235 | <1% | 13 | $4K | |
| 11750 | <1% | 13 | $4K | |
| 82565 | <1% | 2,052 | $4K | |
| 92020 | <1% | 41 | $4K | |
| 92136 | <1% | 471 | $4K | |
| 82962 | <1% | 13,984 | $4K | |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | <1% | 344 | $4K |
| 82627 | <1% | 287 | $4K | |
| 92134 | <1% | 7,609 | $4K | |
| V2632 | Posterior chamber intraocular lens | <1% | 946 | $4K |
| 11055 | <1% | 79 | $4K | |
| 81003 | <1% | 7,843 | $4K | |
| 87631 | <1% | 187 | $4K | |
| 93922 | <1% | 120 | $4K | |
| 87899 | <1% | 1,593 | $4K | |
| 82950 | <1% | 2,651 | $4K | |
| 86677 | <1% | 341 | $4K | |
| 82378 | <1% | 1,826 | $4K | |
| 80164 | <1% | 549 | $4K | |
| 90651 | <1% | 1,052 | $4K | |
| 84100 | <1% | 3,111 | $4K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,339 | $3K |
| C1769 | Guide wire | <1% | 3,346 | $3K |
| 84460 | <1% | 1,925 | $3K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 105 | $3K |
| 87493 | <1% | 822 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 20,794 | $3K |
| 90671 | <1% | 1,191 | $3K | |
| 92523 | <1% | 27 | $3K | |
| 84156 | <1% | 1,704 | $3K | |
| 73590 | <1% | 326 | $3K | |
| 82550 | <1% | 2,242 | $3K | |
| 76870 | <1% | 40 | $3K | |
| 82803 | <1% | 1,457 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 25,528 | $3K |
| 86258 | <1% | 453 | $3K | |
| 82785 | <1% | 240 | $3K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,867 | $3K |
| 72197 | <1% | 13 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 21,133 | $3K |
| 92555 | <1% | 198 | $3K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 12 | $3K |
| 95911 | <1% | 42 | $2K | |
| 84450 | <1% | 1,267 | $2K | |
| 95819 | <1% | 13 | $2K | |
| 84550 | <1% | 1,877 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 15,084 | $2K |
| 72158 | <1% | 13 | $2K | |
| 90656 | <1% | 744 | $2K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 2,888 | $2K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 1,038 | $2K |
| 73120 | <1% | 383 | $2K | |
| 86364 | <1% | 508 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 21,369 | $2K |
| 84144 | <1% | 301 | $2K | |
| 96368 | <1% | 822 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 16,861 | $2K |
| 95908 | <1% | 39 | $2K | |
| 80197 | <1% | 386 | $2K | |
| 87205 | <1% | 2,329 | $2K | |
| 81002 | <1% | 12,935 | $2K | |
| 83615 | <1% | 1,846 | $2K | |
| 86308 | <1% | 415 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,565 | $2K |
| 80069 | <1% | 406 | $2K | |
| 96411 | <1% | 1,765 | $2K | |
| 82947 | <1% | 919 | $2K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 177 | $2K |
| 96402 | <1% | 181 | $2K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 368 | $2K |
| 80400 | <1% | 199 | $2K | |
| 86787 | <1% | 370 | $2K | |
| 72141 | <1% | 13 | $2K | |
| 83721 | <1% | 625 | $2K | |
| 51798 | <1% | 612 | $2K | |
| 97165 | <1% | 44 | $2K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 285 | $2K |
| 86160 | <1% | 448 | $2K | |
| 93246 | <1% | 27 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 10,752 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14,686 | $1K |
| 86304 | <1% | 407 | $1K | |
| 88312 | <1% | 233 | $1K | |
| 97163 | <1% | 41 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 13,071 | $1K |
| 80178 | <1% | 188 | $1K | |
| 92133 | <1% | 1,713 | $1K | |
| 36416 | <1% | 1,426 | $1K | |
| 95909 | <1% | 31 | $1K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 14 | $1K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 12 | $1K |
| 0012A | <1% | 48 | $1K | |
| 84270 | <1% | 181 | $1K | |
| 93798 | <1% | 270 | $1K | |
| 87075 | <1% | 1,154 | $1K | |
| 20550 | <1% | 13 | $1K | |
| 88173 | <1% | 113 | $1K | |
| 0011A | <1% | 56 | $1K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 186 | $1K |
| 73090 | <1% | 143 | $1K | |
| 86334 | <1% | 233 | $1K | |
| 81015 | <1% | 606 | $1K | |
| 90474 | <1% | 817 | $1K | |
| 73080 | <1% | 163 | $1K | |
| 90678 | <1% | 81 | $1K | |
| 74178 | <1% | 13 | $1K | |
| 72070 | <1% | 111 | $1K | |
| 73560 | <1% | 106 | $1K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,179 | $1K |
| 88172 | <1% | 41 | $1K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 162 | $988.80 |
| 83521 | <1% | 247 | $980.79 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,698 | $950.41 |
| 85046 | <1% | 344 | $946.21 | |
| 84165 | <1% | 361 | $931.20 | |
| 73700 | <1% | 15 | $909.17 | |
| 83520 | <1% | 89 | $902.13 | |
| 93225 | <1% | 27 | $895.29 | |
| 90480 | <1% | 54 | $889.59 | |
| 85730 | <1% | 688 | $880.27 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 8,124 | $878.45 |
| 86705 | <1% | 675 | $811.90 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 249 | $808.78 |
| 43248 | <1% | 15 | $786.20 | |
| 83516 | <1% | 122 | $771.68 | |
| 96381 | <1% | 51 | $769.72 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 931 | $764.39 |
| 87522 | Neg quan hep c or qual rna | <1% | 68 | $754.02 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,139 | $743.28 |
| 73562 | <1% | 64 | $714.98 | |
| 82150 | <1% | 143 | $707.77 | |
| 74230 | <1% | 12 | $696.62 | |
| 11720 | <1% | 155 | $694.71 | |
| 93325 | <1% | 13 | $689.82 | |
| 86704 | <1% | 214 | $677.68 | |
| 96417 | <1% | 2,722 | $666.12 | |
| 94727 | <1% | 66 | $656.19 | |
| 82951 | <1% | 94 | $654.01 | |
| 84703 | <1% | 139 | $653.81 | |
| 82105 | <1% | 95 | $641.84 | |
| 99195 | <1% | 20 | $637.96 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,887 | $627.35 |
| 84132 | <1% | 1,199 | $626.50 | |
| 73100 | <1% | 371 | $621.16 | |
| 83993 | <1% | 68 | $614.00 | |
| 86709 | <1% | 635 | $611.54 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,857 | $609.01 |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,258 | $609.00 |
| 97166 | <1% | 16 | $602.91 | |
| 72202 | <1% | 25 | $602.57 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,071 | $586.81 |
| C1729 | Catheter, drainage | <1% | 269 | $580.27 |
| 82330 | <1% | 554 | $576.68 | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 408 | $576.19 |
| 86235 | <1% | 33 | $564.87 | |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | <1% | 431 | $558.09 |
| 51702 | <1% | 63 | $553.66 | |
| 87807 | <1% | 472 | $546.07 | |
| 86708 | <1% | 185 | $545.93 | |
| 83525 | <1% | 88 | $543.59 | |
| 84163 | <1% | 41 | $530.19 | |
| 92250 | <1% | 339 | $529.36 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 4,321 | $518.60 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 153 | $516.24 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 598 | $495.86 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 147 | $494.26 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,580 | $493.46 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 701 | $469.06 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,303 | $468.08 |
| 92650 | <1% | 14 | $434.09 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,637 | $433.99 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 858 | $426.90 |
| 90707 | <1% | 353 | $421.11 | |
| 17003 | <1% | 145 | $410.18 | |
| 73552 | <1% | 25 | $406.38 | |
| 86200 | <1% | 80 | $399.89 | |
| 92556 | <1% | 25 | $373.40 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,334 | $372.60 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 253 | $367.22 |
| 93880 | <1% | 14 | $365.19 | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 27 | $363.22 |
| 87529 | <1% | 13 | $357.78 | |
| 88360 | <1% | 32 | $348.71 | |
| 87329 | <1% | 54 | $326.63 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 369 | $307.75 |
| 72050 | <1% | 39 | $305.56 | |
| 82977 | <1% | 122 | $305.00 | |
| C1758 | Catheter, ureteral | <1% | 453 | $299.22 |
| 86300 | <1% | 48 | $278.61 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 575 | $277.15 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,149 | $273.44 |
| 11721 | <1% | 74 | $266.94 | |
| 86141 | <1% | 88 | $266.85 | |
| 85049 | <1% | 290 | $260.82 | |
| 72170 | <1% | 31 | $249.99 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,022 | $242.39 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,192 | $231.27 |
| 82310 | <1% | 108 | $225.19 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 951 | $215.65 |
| 0296T | <1% | 15 | $211.16 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,495 | $208.39 |
| 84520 | <1% | 128 | $193.56 | |
| 87328 | <1% | 54 | $191.61 | |
| 86146 | <1% | 15 | $187.68 | |
| 73070 | <1% | 61 | $181.20 | |
| 88112 | <1% | 29 | $180.06 | |
| 95874 | <1% | 91 | $173.16 | |
| 82952 | <1% | 51 | $169.61 | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 13 | $162.22 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 108 | $149.87 |
| 90660 | <1% | 16 | $149.83 | |
| 90662 | <1% | 208 | $148.06 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 43 | $130.11 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 130 | $126.62 |
| 90756 | <1% | 22 | $120.15 | |
| 86225 | <1% | 15 | $112.53 | |
| 92611 | <1% | 25 | $108.78 | |
| 86147 | <1% | 15 | $106.69 | |
| 82140 | <1% | 55 | $102.01 | |
| 86036 | <1% | 13 | $96.92 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 697 | $93.60 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 325 | $87.53 |
| 84300 | <1% | 39 | $85.29 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,705 | $84.79 |
| 74019 | <1% | 16 | $80.63 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 155 | $72.88 |
| 85384 | <1% | 13 | $68.84 | |
| 86301 | <1% | 34 | $68.58 | |
| 29125 | <1% | 14 | $65.48 | |
| 84134 | <1% | 14 | $63.21 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 445 | $60.70 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 159 | $55.23 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 238 | $54.22 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 45 | $52.06 |
| 86376 | <1% | 12 | $50.74 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 17 | $48.92 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 12 | $39.36 |
| 86923 | <1% | 14 | $36.33 | |
| 99173 | <1% | 2,796 | $35.49 | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 145 | $35.10 |
| 0077U | <1% | 15 | $29.09 | |
| 11719 | <1% | 29 | $28.08 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 3,464 | $26.36 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 272 | $23.24 |
| 82365 | <1% | 12 | $20.28 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,649 | $19.68 |
| 76376 | <1% | 31 | $18.72 | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 29 | $17.89 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 28 | $17.55 |
| 88313 | <1% | 15 | $16.65 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 3,626 | $16.11 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 158 | $10.54 |
| 82010 | <1% | 29 | $3.47 | |
| 73060 | <1% | 14 | $3.27 | |
| 90710 | <1% | 304 | $0.01 | |
| A9270 | Non-covered item or service | <1% | 12,786 | $0.01 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 2,192 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 371 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 101 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 298 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 174 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 80 | $0.00 |
| J7699 | Noc drugs, inhalation solution administered through dme | 0% | 28 | $0.00 |
| 93356 | 0% | 72 | $0.00 | |
| 90633 | 0% | 787 | $0.00 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 28 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 22 | $0.00 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 0% | 221 | $0.00 |
| 86328 | 0% | 15 | $0.00 | |
| 90672 | 0% | 21 | $0.00 | |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 16 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 1,030 | $0.00 |
| 90619 | 0% | 549 | $0.00 | |
| 90697 | 0% | 856 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 153 | $0.00 |
| 90680 | 0% | 837 | $0.00 | |
| 90620 | 0% | 121 | $0.00 | |
| 90696 | 0% | 284 | $0.00 | |
| 90698 | 0% | 306 | $0.00 | |
| 90716 | 0% | 366 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 15 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 32 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 145 | $0.00 |
| 94760 | 0% | 39 | $0.00 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 174 | $0.00 |
| 90847 | Family psychotherapy with the patient present, 50 minutes | 0% | 13 | $0.00 |
| 0240U | 0% | 150 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 199 | $0.00 |
| 74022 | 0% | 12 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 93 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 219 | $0.00 |
| 90381 | 0% | 45 | $0.00 | |
| 81511 | 0% | 28 | $0.00 | |
| 94644 | 0% | 12 | $0.00 | |
| 71101 | 0% | 12 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 79 | $0.00 |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | 0% | 57 | $0.00 |
| 92285 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJONES, ANDREW (CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.